Literature DB >> 740050

The effects of a permanent and selective depletion of brain catecholamines on the antinociceptive action of morphine.

P Slater, C Blundell.   

Abstract

6-Hydroxydopamine was given to newborn mice. After 60 days their brains were deficient in noradrenaline and dopamine while morphine's antinociceptive action was reduced. 6-Hydroxydopa was administered to adult mice. This depleted brain noradrenaline and reduced morphine's antinociceptive action. Newborn rats received 6-hydroxydopa. After 60 days morphine's antinociceptive action was potentiated, brain noradrenaline was reduced while dopamine had increased. Adult rats were treated with 6-hydroxydopa. This reduced brain noradrenaline but did not affect morphine's antinociceptive action. Guanethidine, which depletes noradrenaline in the peripheral nervous sytem, was given to newborn animals of both species. It had no effect on morphine's antinociceptive action. It is concluded that in the mouse the antinociceptive action of morphine relies in part on normal brain noradrenaline function and dopamine is not directly involved. In the rat morphine's action is affected by neurotoxic drugs which alter brain dopamine function.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 740050     DOI: 10.1007/bf00498815

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  31 in total

1.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

2.  Effect of 6-hydroxydopamine on some actions of tremorine and oxotremorine.

Authors:  P Slater
Journal:  Eur J Pharmacol       Date:  1974-02       Impact factor: 4.432

3.  Effect of chemical sympathectomy on morphine antinociception and tolerance development in the rat.

Authors:  H N Bhargava; A H Afifi; E L Way
Journal:  Biochem Pharmacol       Date:  1973-11-01       Impact factor: 5.858

4.  Decrease in morphine's analgesic action and increase in its cataleptic action by 6-hydroxydopamine injected bilaterally into caudate and putamen areas; partial restoration by L-DOPA plus decarboxylase inhibition.

Authors:  K Nakamura; R Kuntzman; A Maggio; A H Conney
Journal:  Neuropharmacology       Date:  1973-12       Impact factor: 5.250

5.  Effect of 6-hydroxydopamine on morphine analgesia.

Authors:  I H Ayhan
Journal:  Psychopharmacologia       Date:  1972

6.  Selective action of 6-hydroxydopa on noradrenergic terminals: mapping of preterminal axons of the brain.

Authors:  D Jacobowitz; R Kostrzewa
Journal:  Life Sci I       Date:  1971-12-01

7.  Effect of 6-hydroxydopamine on behaviour and cerebral amine content in rats.

Authors:  W P Burkard; M Jalfre; J Blum
Journal:  Experientia       Date:  1969-12-15

8.  Mechanisms of selective depletion of brain regional noradrenaline by systemic 6-hydroxydopamine in newborn rats.

Authors:  M C Liew; R Laverty
Journal:  Eur J Pharmacol       Date:  1975-08       Impact factor: 4.432

9.  Morphine and methadone-induced antinociception in rats permanently depleted of brain dopamine.

Authors:  J A Rosecrans; M A Elchisak; G J Harry
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-10

10.  Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure.

Authors:  F E Bloom; S Algeri; A Groppetti; A Revuelta; E Costa
Journal:  Science       Date:  1969-12-05       Impact factor: 47.728

View more
  2 in total

1.  The effects of intraventricular 6-hydroxydopamine and 5,6-dihydroxytryptamine on morphine induced locomotor stimulation.

Authors:  P Slater; C Blundell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-07       Impact factor: 3.000

2.  The effect of 6-hydroxydopamine on the antinociceptive action of oxotremorine.

Authors:  P Slater
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.